Electronic Resource
Discontinuation of BRAF/MEK-directed targeted therapy after complete remission of metastatic melanoma — a retrospective multicenter ADOReg study
| العنوان: | Discontinuation of BRAF/MEK-directed targeted therapy after complete remission of metastatic melanoma — a retrospective multicenter ADOReg study |
|---|---|
| المؤلفون: | Stege, Henner Maximilian, Haist, Maximilian, Schultheis, Michael, Fleischer, Maria Isabel, Mohr, Peter, Meier, Friedegund, Schadendorf, Dirk, Ugurel, Selma, Livingstone, Elisabeth, Zimmer, Lisa, Herbst, Rudolf, Pföhler, Claudia Ursula, Kähler, Katharina, Weichenthal, Michael, Terheyden, Patrick, Nashan, Dorothée, Debus, Dirk, Kaatz, Martin, Ziller, Fabian, Haferkamp, Sebastian, Forschner, Andrea Lydia, Leiter, Ulrike, Kreuter, Alexander, Ulrich, Jens, Kleemann, Johannes, Bradfisch, Fabienne, Grabbe, Stephan, Loquai, Carmen |
| بيانات النشر: | 2021-05-12 |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | Simple Summary: The introduction of BRAF/MEK-directed targeted therapy (TT) has significantly improved the management of patients with advanced BRAF-V600-mutant melanoma. Although resistance occurs, there is a subgroup of patients showing a complete response (CR) to TT and who maintain durable disease control. For these patients with durable CR, it is not clear whether it is safe to cease therapy. In this retrospective, multicenter study we have analyzed 37 patients who received TT and achieved a CR upon treatment. We identified 15 patients with a durable CR to TT. Overall, patients who discontinued TT (n = 26) were at higher risk of tumor progression compared to patients receiving ongoing TT. Sustained CR was however not restricted to patients with ongoing TT (n = 11) but was also found in patients who ceased TT (n = 4). Finally, our analysis indicated which patients with an initial CR might be most likely to maintain durable CR upon discontinuation of TT. Abstract: The advent of BRAF/MEK inhibitors (BRAFi/MEKi) has significantly improved progression-free (PFS) and overall survival (OS) for patients with advanced BRAF-V600-mutant melanoma. Long-term survivors have been identified particularly among patients with a complete response (CR) to BRAF/MEK-directed targeted therapy (TT). However, it remains unclear which patients who achieved a CR maintain a durable response and whether treatment cessation might be a safe option in these patients. Therefore, this study investigated the impact of treatment cessation on the clinical course of patients with a CR upon BRAF/MEK-directed-TT. We retrospectively selected patients with BRAF-V600-mutant advanced non-resectable melanoma who had been treated with BRAFi ± MEKi therapy and achieved a CR upon treatment out of the multicentric skin cancer registry ADOReg. Data on baseline patient characteristics, duration of TT, treatment cessation, tumor progression (TP) and response to second-line treatments were collected and analyzed. |
| مصطلحات الفهرس: | ddc:610, article, doc-type:article |
| URL: | |
| الاتاحة: | Open access content. Open access content http://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/restrictedAccess |
| ملاحظة: | application/octet-stream English |
| Other Numbers: | DEJWG oai:publikationen.ub.uni-frankfurt.de:62111 urn:nbn:de:hebis:30:3-621111 1362825794 |
| المصدر المساهم: | JOHANN WOLFGANG GOETHE UNIV From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1362825794 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |